Choisissez votre pays / Select your country

Ninalia NIPT The prenatal trisomy screening test based on maternal blood sample

Monitoring your patients

Patient’s journey according to the decision tree:

Screening
Non-invasive sample
  • Ultrasound
  • Maternal Serum Markers  (MSM)
  • Non-Invasive Prenatal Testing (NIPT)
Diagnosis
Invasive sample
  • Amniocentesis
  • Chorionic villus sampling

Trisomy 21 diagnostic strategy with NIPT

N.B: For signs on ultrasound or risk greater than 1/10 according to maternal serum markers, confirmation of the diagnosis by fœtal karyotype testing on invasive sample is required.

Please contact Eurofins Biomnis geneticists at international@biomnis.com should you need further information.

The advantages of Ninalia NIPT in the diagnosis of trisomies 13, 18 and 21

  • An excellent detection rate : 99%*
  • Reduced exposure to the risk of foetal loss by avoiding useless invasive procedure
  • Can be used for twin pregnancies (combined screening in the 1st trimester is not currently recommended for twin pregnancies).
  • Can be performed within the context of pregnancies with donated eggs and pregnancies in transplant patients, unlike other tests available on the market.
  • Eurofins Biomnis genetists at your service to advise you on diagnostic approach

Find your nearest testing centre As Ninalia NIPT requires a specific sample tube, don’t forget to make an appointment in advance with your local laboratory for specimen collection.

Vous avez refusé de partager votre position.
Désolé. Nous n'arrivons pas à savoir où vous êtes...
Il faut nous autoriser à voir votre position...
Votre navigateur ne possède pas cette fonctionnalité.

Partner laboratories

out of laboratories in total out of laboratories in total